BioAge Labs Inc. Reports Second Quarter 2025 Financial Results and Provides Business Updates
In a recent announcement, BioAge Labs, Inc., a clinical-stage biopharmaceutical company focused on developing therapeutic solutions for metabolic diseases, has reported its financial results for the second quarter of 2025. The company, which operates within the health care sector and is listed on the Nasdaq, has been making strides in targeting the biology of human aging to address conditions such as obesity.
As of August 4, 2025, BioAge Labs’ stock closed at $4.44, a significant distance from its 52-week high of $26.62 recorded on October 21, 2024, and its 52-week low of $2.88 on April 8, 2025. The company’s market capitalization stands at approximately $157.74 million, with a price-to-earnings ratio of 0.874.
BioAge Labs’ lead product, BGE-102, is a novel, orally available small molecule NLRP3 inhibitor known for its high potency and ability to penetrate the brain. In preclinical obesity models, BGE-102 has shown promising results, achieving weight loss both as a standalone treatment and in combination with a GLP-1R agonist. The company’s pipeline also includes other innovative small-molecule NLRP3 inhibitors and novel APJ agonists aimed at treating metabolic disorders. Notably, APJ agonism has demonstrated the potential to more than double the weight loss effects of a GLP-1R agonist, while also improving body composition and muscle function.
In addition to its financial updates, BioAge Labs provided insights into its ongoing research and development efforts. The company remains committed to advancing its therapeutic candidates to address the growing global burden of metabolic diseases.
Collaboration in Precision Health Research
In related news, Standard BioTools Inc., a company listed on the Nasdaq under the ticker LAB, has announced a significant collaboration with Precision Health Research, Singapore (PRECISE-SG100K). This partnership involves the use of the SomaScan™ 11K Assay to analyze 100,000 plasma samples from the PRECISE-SG100K biobank. This initiative aims to transform precision health and medicine by enabling the discovery of novel genetic associations and biomarkers.
Professor John Chambers, Chief Scientific Officer of PRECISE and Lead Investigator of the SG100K population cohort study, emphasized the importance of this collaboration. “Our vision is to shape the future of precision medicine through one of the world’s most ambitious population health research programs,” he stated. The selection of SomaScan was based on its unmatched proteome coverage, superior reproducibility, and high-quality service, making it the ideal platform for this landmark initiative.
This collaboration underscores the growing role of proteomics in leading global health initiatives and reinforces SomaScan’s strategic position in the high-impact biobank segment. As BioAge Labs continues to focus on its therapeutic developments, the broader biotech community is witnessing significant advancements in precision health research, promising new avenues for understanding and treating complex diseases.